Halozyme Therapeutics (NASDAQ:HALO) Issues FY24 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share guidance of $3.55-3.90 for the period, compared to the consensus earnings per share estimate of $3.52. The company issued revenue guidance of $915-985 million, compared to the consensus revenue estimate of $954.43 million.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HALO. TheStreet downgraded Halozyme Therapeutics from a b- rating to a c+ rating in a research report on Monday, January 22nd. Benchmark restated a buy rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, April 16th. StockNews.com upgraded Halozyme Therapeutics from a hold rating to a buy rating in a research report on Friday, February 23rd. JMP Securities restated a market outperform rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, February 21st. Finally, The Goldman Sachs Group dropped their price objective on Halozyme Therapeutics from $45.00 to $40.00 and set a neutral rating for the company in a research note on Thursday, January 18th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Halozyme Therapeutics currently has a consensus rating of Moderate Buy and an average price target of $53.29.

Halozyme Therapeutics Stock Up 0.9 %

HALO traded up $0.35 on Tuesday, hitting $41.21. 1,281,201 shares of the company were exchanged, compared to its average volume of 1,207,506. Halozyme Therapeutics has a twelve month low of $29.85 and a twelve month high of $45.00. The company has a market cap of $5.24 billion, a price-to-earnings ratio of 19.37, a price-to-earnings-growth ratio of 0.47 and a beta of 1.26. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. The firm has a 50-day moving average price of $40.01 and a two-hundred day moving average price of $37.94.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The business had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. On average, equities analysts predict that Halozyme Therapeutics will post 3.43 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the transaction, the senior vice president now directly owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 30,000 shares of company stock valued at $1,196,800. 2.70% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.